Scarica l'app Stockscreener
32.68
8.77%
-3.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$35.82
Aprire:
$35.64
Volume 24 ore:
2.83M
Relative Volume:
1.25
Capitalizzazione di mercato:
$3.36B
Reddito:
$164.01M
Utile/perdita netta:
$-65.04M
Rapporto P/E:
-47.57
EPS:
-0.687
Flusso di cassa netto:
$-383.84M
1 W Prestazione:
-6.06%
1M Prestazione:
+10.82%
6M Prestazione:
+18.62%
1 anno Prestazione:
+48.34%
Intervallo 1D:
$31.34
$35.64
Intervallo di 1 settimana:
$31.34
$38.26
Portata 52W:
$15.60
$38.26
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
32.68 | 3.36B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? - Yahoo Finance
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout | AI
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
BEAM Reiterated by B of A Securities -- Price Target Maintained at $47 - GuruFocus
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Yahoo Finance
BofA reiterates Beam Therapeutics stock rating after arbitration ruling - Investing.com
BofA reiterates Beam Therapeutics stock rating after arbitration ruling By Investing.com - Investing.com India
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com South Africa
Why is Beam Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics - The Manila Times
Prime Medicine (NASDAQ: PRME) cleared of breach in Beam arbitration ruling - Stock Titan
Prime Medicine clears Beam dispute, keeps PM647 for AATD - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics - Yahoo Finance
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal - Yahoo Finance
H.C. Wainwright reiterates Beam Therapeutics stock rating on BLA progress - Investing.com
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Russell Value Index Additions Could Be A Game Changer For Beam Therapeutics (BEAM) - simplywall.st
Beam Therapeutics stock hits 52-week high at 36.89 USD - Investing.com UK
Beam Therapeutics stock hits 52-week high at 36.89 USD By Investing.com - Investing.com Nigeria
Understanding the Setup: (BEAM) and Scalable Risk - Stock Traders Daily
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $49.87, Implies 43% Upside - TradingView
FMR LLC Reduces Stake in Beam Therapeutics Inc. - GuruFocus
Beam Therapeutics (NASDAQ: BEAM) CMO sells 373 shares for tax withholding - Stock Titan
BEAMBeam Therapeutics Inc Latest SEC Filings - Finviz
BEAM Stock Price, Quote & Chart - ChartMill
Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan - Stock Titan
Form 144 BEAM THERAPEUTICS INC. For: 30 June By Investing.com - Investing.com Nigeria
Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More - Insider Monkey
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock - Moomoo
Form 144 BEAM THERAPEUTICS INC. For: 29 June By Investing.com - Investing.com South Africa
FMR LLC sells $10.04 million in Beam Therapeutics shares By Investing.com - Investing.com Australia
BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise - Stock Titan
Form 4 Beam Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
FMR LLC sells $10.04 million in Beam Therapeutics shares - Investing.com
FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale - Stock Titan
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 2000 Value Benchmark - marketscreener.com
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 3000E Value Benchmark - marketscreener.com
Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):